[en] CONTEXT: Inhibitors of the protease neprilysin (NEP) are used for treating heart failure, but are also linked to improvements in metabolism. NEP may cleave proglucagon-derived peptides, including the glucose and amino acid (AA)-regulating hormone glucagon. Studies investigating NEP inhibition on glucagon metabolism are warranted. OBJECTIVE: This work aims to investigate whether NEP inhibition increases glucagon levels. METHODS: Plasma concentrations of glucagon and AAs were measured in eight healthy men during a mixed meal with and without a single dose of the NEP inhibitor/angiotensin II type 1 receptor antagonist, sacubitril/valsartan (194 mg/206 mg). Long-term effects of sacubitril/valsartan (8 weeks) were investigated in individuals with obesity (n = 7). Mass spectrometry was used to investigate NEP-induced glucagon degradation, and the derived glucagon fragments were tested pharmacologically in cells transfected with the glucagon receptor (GCGR). Genetic deletion or pharmacological inhibition of NEP with or without concomitant GCGR antagonism was tested in mice to evaluate effects on AA metabolism. RESULTS: In healthy men, a single dose of sacubitril/valsartan significantly increased postprandial concentrations of glucagon by 228%, concomitantly lowering concentrations of AAs including glucagonotropic AAs. Eight-week sacubitril/valsartan treatment increased fasting glucagon concentrations in individuals with obesity. NEP cleaved glucagon into 5 inactive fragments (in vitro). Pharmacological NEP inhibition protected both exogenous and endogenous glucagon in mice after an AA challenge, while NEP-deficient mice showed elevated fasting and AA-stimulated plasma concentrations of glucagon and urea compared to controls. CONCLUSION: NEP cleaves glucagon, and inhibitors of NEP result in hyperglucagonemia and may increase postprandial AA catabolism without affecting glycemia.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Kjeldsen, Sasha A. S.
Hansen, Lasse H.
Esser, Nathalie ; University of Washington - UW > Department of Medicine > Division of Metabolism, Endocrinology and Nutrition
Kenny AJ. Regulatory peptide metabolism at cell surfaces: The key role of endopeptidase-24.11. Biomed Biochim Acta. 1986;45(11-12):1503-1513.
Esser N, Zraika S. Neprilysin inhibition: A new therapeutic option for type 2 diabetes? Diabetologia. 2019;62(7):1113-1122.
Bayés-Genís A, Barallat J, Galán A, et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65(7):657-665.
Dalzell JR, Seed A, Berry C, et al. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovasc Ther. 2014;32(1):13-18.
Wewer Albrechtsen NJ, Mark PD, Terzic D, et al. Sacubitril/ valsartan augments postprandial plasma concentrations of active GLP-1 when combined with sitagliptin in men. J Clin Endocrinol Metab. 2019;104(9):3868-3876.
Nougué H, Pezel T, Picard F, et al. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: A mechanistic clinical study. Eur J Heart Fail. 2019;21(5):598-605.
McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15(9):1062-1073.
Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/ valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: A post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333-340.
Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 1995;58(3):149-156.
Kerr MA, Kenny AJ. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J. 1974;137(3):477-488.
Trebbien R, Klarskov L, Olesen M, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab. 2004;287(3):E431-E438.
Winther-Sørensen M, Galsgaard KD, Santos A, et al. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. Mol Metab. 2020;42:101080.
Suppli MP, Bagger JI, Lund A, et al. Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis. Diabetes. 2020;69(6):1090-1099.
Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. J Clin Invest. 2012;122(1):4-12.
Unger RH, Orci L. Physiology and pathophysiology of glucagon. Physiol Rev. 1976;56(4):778-826.
Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet. 1975;1(7897):14-16.
Möller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med. 1970;283(3):109-115.
Möller WA, Faloona GR, Unger RH. The effect of alanine on glucagon secretion. J Clin Invest. 1971;50(10):2215-2218.
Unger RH, Aguilar-Parada E, Möller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest. 1970;49(4):837-848.
Kazda CM, Ding Y, Kelly RP, et al. Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12-and 24-week phase 2 studies. Diabetes Care. 2016;39(7):1241-1249.
Longuet C, Robledo AM, Dean ED, et al. Liver-specific disruption of the murine glucagon receptor produces ?-cell hyperplasia: evidence for a circulating ?-cell growth factor. Diabetes. 2013;62(4):1196-1205.
Solloway MJ, Madjidi A, Gu C, et al. Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of ?-cell mass. Cell Rep. 2015;12(3):495-510.
Galsgaard KD, Winther-Sørensen M, Ørskov C, et al. Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-Alpha-cell axis. Am J Physiol Endocrinol Metab. 2018;314(1):E93-E103.
Jordan J, Stinkens R, Jax T, et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. Clin Pharmacol Ther. 2017;101(2):254-263.
Balk-Møller E, Agerlin Windeløv J, Svendsen B, et al. Glucagonlike peptide-1 and atrial natriuretic peptide in a female mouse model of obstructive pulmonary disease. J Endocr Soc. 2019;4(1):bvz034.
Lu B, Gerard NP, Kolakowski LF Jr, et al. Neutral endopeptidase modulation of septic shock. J Exp Med. 1995;181(6):2271-2275.
Zraika S, Koh DS, Barrow BM, Lu B, Kahn SE, Andrikopoulos S. Neprilysin deficiency protects against fat-induced insulin secretory dysfunction by maintaining calcium influx. Diabetes. 2013;62(5):1593-1601.
Kodra JT, Jørgensen AS, Andersen B, et al. Novel glucagon receptor antagonists with improved selectivity over the glucosedependent insulinotropic polypeptide receptor. J Med Chem. 2008;51(17):5387-5396.
Steenberg VR, Jensen SM, Pedersen J, et al. Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes. Diabetologia. 2016;59(2):363-370.
Galsgaard KD, Winther-Sørensen M, Pedersen J, et al. Glucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling. Am J Physiol Endocrinol Metab. 2019;316(4):E660-E673.
Ksander GM, Ghai RD, deJesus R, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995;38(10):1689-1700.
Bourne A, Kenny AJ. The hydrolysis of brain and atrial natriuretic peptides by porcine choroid plexus is attributable to endopeptidase-24.11. Biochem J. 1990;271(2):381-385.
Stephenson SL, Kenny AJ. The hydrolysis of ?-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J. 1987;243(1):183-187.
Gabe MBN, Sparre-Ulrich AH, Pedersen MF, et al. Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-Affinity binding to primate but not rodent GIP receptors. Biochem Pharmacol. 2018;150:97-107.
Kissow H, Hartmann B, Holst JJ, et al. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept. 2012;179(1-3):91-100.
Wewer Albrechtsen NJ, Kuhre RE, Windeløv JA, et al. Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes. Am J Physiol Endocrinol Metab. 2016;311(2):E302-E309.
Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest. 1991;87(2):415-423.
Wewer Albrechtsen NJ, Hartmann B, Veedfald S, et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia. 2014;57(9):1919-1926.
Smart KF, Aggio RB, Van Houtte JR, Villas-Bôas SG. Analytical platform for metabolome analysis of microbial cells using methyl chloroformate derivatization followed by gas chromatographymass spectrometry. Nat Protoc. 2010;5(10):1709-1729.
Johnsen LG, Skou PB, Khakimov B, Bro R. Gas chromatography mass spectrometry data processing made easy. J Chromatogr A. 2017;1503:57-64.
Kjeldsen SAS, Hansen LH, Esser N, et al. Neprilysin inhibition increases glucagon levels in humans and mice with potential effects on amino acid metabolism, supplementary file. Uploaded April 17, 2021. doi:10.6084/m9.figshare.13607534
Vanneste Y, Michel A, Dimaline R, Najdovski T, Deschodt-Lanckman M. Hydrolysis of ?-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site. Biochem J. 1988;254(2):531-537.
Hansen LH, Madsen TD, Goth CK, et al. Discovery of O-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor. J Biol Chem. 2019;294(34):12567-12578.
Kim J, Okamoto H, Huang Z, et al. Amino acid transporter Slc38a5 controls glucagon receptor inhibition-induced pancreatic ? cell hyperplasia in mice. Cell Metab. 2017;25(6):1348-1361.e8.
Battezzati A, Simonson DC, Luzi L, Matthews DE. Glucagon increases glutamine uptake without affecting glutamine release in humans. Metabolism. 1998;47(6):713-723.
Aquilani R, La Rovere MT, Corbellini D, et al. Plasma amino acid abnormalities in chronic heart failure. mechanisms, potential risks and targets in human myocardium metabolism. Nutrients. 2017;9(11):1251.
Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005;48(9):1882-1890.
Willard JR, Barrow BM, Zraika S. Improved glycaemia in highfat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels. Diabetologia. 2017;60(4):701-708.
Windeløv JA, Wewer Albrechtsen NJ, Kuhre RE, et al. Why is it so difficult to measure glucagon-like peptide-1 in a mouse? Diabetologia. 2017;60(10):2066-2075.
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
Uehlinger DE, Weidmann P, Gnädinger MP, et al. Increase in circulating insulin induced by atrial natriuretic peptide in normal humans. J Cardiovasc Pharmacol. 1986;8(6):1122-1129.
Coué M, Barquissau V, Morigny P, et al. Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes. Sci Rep. 2018;8(1):1097.
El K, Capozzi ME, Campbell JE. Repositioning the alpha cell in postprandial metabolism. Endocrinology. 2020;161(11):bqaa169.
Capozzi ME, Wait JB, Koech J, et al. Glucagon lowers glycemia when ?-cells are active. JCI Insight. 2019;5(16):e129954.
Ang T, Bruce CR, Kowalski GM. Postprandial aminogenic insulin and glucagon secretion can stimulate glucose flux in humans. Diabetes. 2019;68(5):939-946.
Galsgaard KD, Jepsen SL, Kjeldsen SAS, Pedersen J, Wewer Albrechtsen NJ, Holst JJ. Alanine, arginine, cysteine, and proline, but not glutamine, are substrates for, and acute mediators of, the liver-?-cell axis in female mice. Am J Physiol Endocrinol Metab. 2020;318(6):E920-E929.
Rocha DM, Faloona GR, Unger RH. Glucagon-stimulating activity of 20 amino acids in dogs. J Clin Invest. 1972;51(9):2346-2351.
Pozsgay M, Michaud C, Liebman M, Orlowski M. Substrate and inhibitor studies of thermolysin-like neutral metalloendopeptidase from kidney membrane fractions. Comparison with bacterial thermolysin. Biochemistry. 1986;25(6):1292-1299.
Feracci H, Maroux S. Rabbit intestinal aminopeptidase N. Purification and molecular properties. Biochim Biophys Acta. 1980;599(2):448-463.
Zhou A, Pacini G, Ahrén B, D Argenio DZ. Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice. Diabetologia. 2014;57(4):801-808.
Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic ? cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A. 2003;100(3):1438-1443.
Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68(6):639-653.
Spillantini MG, Sicuteri F, Salmon S, Malfroy B. Characterization of endopeptidase 3.4.24.11 ("enkephalinase") activity in human plasma and cerebrospinal fluid. Biochem Pharmacol. 1990;39(8):1353-1356.
Yandle T, Richards M, Smith M, Charles C, Livesey J, Espiner E. Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem. 1992;38(9):1785-1791.
Snider P, Conway SJ. Probing human cardiovascular congenital disease using transgenic mouse models. Prog Mol Biol Transl Sci. 2011;100:83-110.
Gromada J, Franklin I, Wollheim CB. ?-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev. 2007;28(1):84-116.
Ravier MA, Rutter GA. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic ?-cells. Diabetes. 2005;54(6):1789-1797.
Hahn HJ, Ziegler M. Investigations on isolated islets of langerhans in vitro. 16.Modification of the glucose-dependent inhibition of glucagon secretion. Biochim Biophys Acta. 1977;499(3):362-372.
Lainchbury JG, Richards AM, Nicholls MG, Espiner EA, Yandle TG. Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment. J Clin Endocrinol Metab. 1999;84(2):723-729.
Charles CJ, Espiner EA, Richards AM, Sybertz EJ. Endopeptidase inhibition in angiotensin-induced hypertension. Effect of SCH 39370 in sheep. Hypertension. 1995;26(1):89-94.
Simmons PS, Miles JM, Gerich JE, Haymond MW. Increased proteolysis. An effect of increases in plasma cortisol within the physiologic range. J Clin Invest. 1984;73(2):412-420.
Esser N, Barrow BM, Choung E, Shen NJ, Zraika S. Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner. Islets. 2018;10(5):175-180.
Weiner ID, Mitch WE, Sands JM. Urea and ammonia metabolism and the control of renal nitrogen excretion. Clin J Am Soc Nephrol. 2015;10(8):1444-1458.
